Table 3. Survival analysis of the patient cohorts included in DTC analyses.
| Univariate analysis |
Multivariable analysis |
||||
|---|---|---|---|---|---|
| Data set | Risk factor | Median survival (months) | P-value | Relative risk (95% confidence interval) | P-value |
| #1, n=44 | Age: ⩽65 (n=24) vs ⩾65 (n=20) | 31.0 vs 13.0 | 0.13 | — | NS |
| Sex: m (n=34) vs f (n=10) | 16.5 vs 31.0 | 0.62 | — | NS | |
| T-category: pT1–2 (n=22) vs pT3–4 (n=22) | 22.0 vs 13.0 | 0.27 | — | NS | |
| N-category: pN0 (n=14) vs pN1–3 (n=30) | NA vs 13.5 | <0.01 | 4.03 (1.40–11.63) | 0.01 | |
| M-category: M0 (n=38) vs M1 (n=6) | 22.0 vs 13.0 | 0.38 | — | NS | |
| Grading: G1–2 (n=18) vs G3–4 (n=26) | 30.0 vs 16.5 | 0.46 | — | NS | |
| DTCnegative (n=30) vs DTCpositive (n=14) | 22.0 vs 14.0 | 0.38 | — | NS | |
| DTCpositive PAG <26/DTCnegative (n=40) vs DTCpositive PAG⩾26 (n=4) | 22.0 vs 9.5 | 0.02 | — | NS | |
| DTCpositive PAG <26 (n=10) vs DTCpositive PAG⩾26 (n=4) | 26.0 vs 9.5 | 0.04 | 142.35 (4.05–5009.81) | 0.01 | |
| #2, n=29 | Age: ⩽62 (n=15) vs >62 (n=14) | 42.5 vs 20.1 | 0.21 | — | NS |
| Sex: m (n=27) vs f (n=2) | 26.1 vs 39.9 | 0.38 | — | NS | |
| T-category: pT1–2 (n=22) vs pT3–4 (n=7) | 42.5 vs 21.9 | 0.13 | 5.50 (1.55–19.55) | 0.01 | |
| N-category: pN0 (n=8) vs pN1–3 (n=21) | 62.0 vs 24.8 | 0.16 | — | NS | |
| M-category: M0 (n=25) vs M1 (n=4) | 39.9 vs 18.5 | 0.54 | — | NS | |
| Grading: G1–2 (n=12) vs G3–4 (n=17) | 39.9 vs 24.8 | 0.32 | — | NS | |
| DTCnegative (n=20) vs DTCpositive (n=9) | 42.5 vs 21.9 | 0.02 | 3.39 (1.03–11.15) | 0.04 | |
| DTCpositive PAG <19/DTCnegative (n=26) vs DTCpositive PAG⩾19 (n=3) | 39.9 vs 9.1 | <0.01 | 10.44 (1.60–68.07) | 0.01 | |
| DTCpositive PAG <19 (n=6) vs DTCpositive PAG⩾19 (n=3) | 25.1 vs 9.1 | 0.02 | — | NS | |
| #1 and #2, n=73 | Age: ⩽64 (n=38) vs >64 (n=35) | 39.9 vs 20.4 | 0.27 | — | NS |
| Sex: m (n=61) vs f (n=12) | 22.0 vs 36.0 | 0.44 | — | NS | |
| T-category: pT1–2 (n=44) vs pT3–4 (n=29) | 32.0 vs 19.7 | 0.10 | — | NS | |
| N-category: pN0 (n=22) vs pN1–3 (n=51) | NA vs 19.7 | <0.01 | 2.73 (1.26–5.94) | 0.01 | |
| M-category: M0 (n=63) vs M1 (n=10) | 28.0 vs 16.1 | 0.22 | — | NS | |
| Grading: G1–2 (n=30) vs G3–4 (n=43) | 31.6 vs 19.7 | 0.17 | — | NS | |
| DTCnegative (n=50) vs DTCpositive (n=23) | 32.0 vs 17.2 | 0.05 | — | NS | |
| DTCpositive PAG <15/DTCnegative (n=63) vs DTCpositive PAG⩾15 (n=10) | 30.0 vs 11.1 | <0.01 | 2.65 (1.24–5.66) | 0.01 | |
| DTCpositive PAG <15 (n=13) vs DTCpositive PAG⩾15 (n=10) | 26.1 vs 11.1 | 0.02 | 3.23 (1.15–9.10) | 0.03 | |
Abbreviations: DTC=disseminated tumour cell; f=female; m=male; M-category=distant metastases; NA=not available; N-category=lymph node metastases; NS=not significant in multivariable analysis; PAG=percentage of aberrant genome per cell; T-category=primary tumour size. P-values ⩽0.05 are presented in bold.